Amphastar Pharmaceuticals AMPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $171.17M+0.4% | $183.11M-1.8% | $191.84M+0.3% | $174.41M-4.4% | $170.53M-0.8% | ||
| $100.85M+18.3% | $97.44M-2.4% | $93.19M+4.4% | $87.92M+0.8% | $85.28M+4.3% | ||
| $70.32M-17.5% | $85.67M-1.1% | $98.65M-3.2% | $86.49M-9.1% | $85.25M-5.4% | ||
| 41.1%-8.9pp | 46.8%+0.3pp | 51.4%-1.9pp | 49.6%-2.6pp | 50%-2.4pp | ||
| $26.74M+33.0% | $23.31M+28.5% | $22.35M+6.1% | $20.08M+13.8% | $20.1M+17.9% | ||
| $11.93M+0.5% | $10.28M-1.4% | $11.51M+27.9% | $10.24M+13.6% | $11.87M+26.6% | ||
| $18.03M+12.7% | $16.47M+27.3% | $39.47M+166% | $13.99M+5.3% | $16M+2.0% | ||
| $56.69M+18.2% | $50.06M+20.6% | $73.33M+63.3% | $44.31M+10.9% | $47.96M+13.9% | ||
| $56.69M+18.2% | $50.06M+20.6% | $73.33M+63.3% | $44.31M+10.9% | $47.96M+13.9% | ||
| $13.63M-63.5% | $35.61M-21.1% | $25.32M-55.6% | $42.18M-23.6% | $37.29M-22.3% | ||
| 8%-13.9pp | 19.4%-4.8pp | 13.2%-16.6pp | 24.2%-6.1pp | 21.9%-6.1pp | ||
| $6.55M+4.2% | $6.63M+3.2% | $6.28M-6.2% | $6.28M-27.0% | $6.29M-27.0% | ||
| $2.4M+14.9% | $2.42M+5.7% | $2.25M-7.5% | $1.92M-42.4% | $2.09M-18.3% | ||
| -$3.58M+44.4% | -$3.69M-212% | -$3.81M+59.3% | -$2.85M+42.7% | -$6.43M-4,699% | ||
| $10.05M-67.4% | $31.91M-27.4% | $21.51M-54.9% | $39.34M-21.7% | $30.86M-35.5% | ||
| $3.63M-34.9% | $7.49M+24.8% | $4.16M-42.6% | $8.31M-32.4% | $5.58M+35.2% | ||
| $6.42M-74.6% | $24.43M-35.7% | $17.35M-57.1% | $31.03M-18.2% | $25.29M-41.4% | ||
| 3.8%-11.1pp | 13.3%-7.0pp | 9%-12.1pp | 17.8%-3.0pp | 14.8%-10.3pp | ||
| $0.14-72.5% | $0.51-31.1% | $0.37-52.6% | $0.64-12.3% | $0.51-37.0% | ||
| $0.14-73.6% | $0.53-32.9% | $0.38-54.2% | $0.66-14.3% | $0.53-41.1% | ||
| 46.5M-6.9% | 48.2M-7.4% | 47.7M-8.1% | 48.1M-7.5% | 49.9M-5.9% | ||
| 45.3M-4.9% | 46.7M-3.5% | 46.5M-4.4% | 46.9M-4.0% | 47.6M-1.2% | ||
| $575K+126% | $515K-82.5% | $231K+105% | $1.51M+407% | -$2.23M-138% | ||
| $13.63M-63.5% | $35.61M-21.1% | $25.32M-55.6% | $42.18M-23.6% | $37.29M-22.3% | ||
| $27.98M-45.0% | $49.95M-14.7% | $39.45M-44.0% | $56.8M-16.9% | $50.9M-16.5% | ||
| $27.98M-45.0% | $49.95M-14.7% | $39.45M-44.0% | $56.8M-16.9% | $50.9M-16.5% | ||
| 16.3%-13.5pp | 27.3%-4.1pp | 20.6%-16.3pp | 32.6%-4.9pp | 29.8%-5.6pp | ||
| $13.63M-63.5% | $35.61M-21.1% | $25.32M-55.6% | $42.18M-23.6% | $37.29M-22.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amphastar Pharmaceuticals's revenue?
- Amphastar Pharmaceuticals (AMPH) generated $720.5M in revenue over the trailing twelve months, down 1.4% year over year.
- Is Amphastar Pharmaceuticals profitable?
- Amphastar Pharmaceuticals reported $79.2M in net income over the trailing twelve months, a 11.0% net margin.
- What are Amphastar Pharmaceuticals's profit margins?
- Gross margin is 47.3% and operating margin is 16.2%, with a 11.0% net margin.
- What is Amphastar Pharmaceuticals's earnings per share?
- Amphastar Pharmaceuticals's diluted EPS over the trailing twelve months is $1.66.
- Where does Amphastar Pharmaceuticals's income statement data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
